Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Items 501–529 of 529
Neuroprotective potential of incretinomimetics
Kokin, A. S., Суплотова, Л. А., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-159
GLP1R Agonists Activate Human POMC NeuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Chen, J., Alcaino, C., Macarelli, V., Mali, I. D., Gribble, F. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855485
Nogueira, L., & Boone, D. L. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107223
Vers un traitement neuroprotecteur dans la MPI ? La cible GLP-1
Meissner, W. G. (2025) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2025.01.009
Pessoa‐Gonçalves, Y. M., Flávio‐Reis, V. H. P., Desidério, C. S., de Sousa, M. A. D., Oliveira, C. J. F., Cury, R. G., & Rodrigues, W. F. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08568-y
Pilśniak, J., Węgrzynek‐Gallina, J., Bednarczyk, B., Buczek, A., Pilśniak, A., Chmiela, T., Jarosińska, A., Siuda, J. S., & Holecki, M. T. (2025) · Life · doi:10.3390/life15121893 · Cited by 2
Barer, Y., Ast, T., Chodick, G., Twig, G., & Giladi, N. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108171
Liu, S., Chen, Q., Liu, H., Chen, Z., Ding, N., Sun, T., & Wang, L. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.02.033
Zou, Y., & Su, H. (2026) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_307_2025
Rissardo, J. P., & Caprara, A. L. F. (2026) · Brain Circulation · doi:10.4103/bc.bc_75_25
Hung, T.-H., Chen, C.-R., Hsu, C., Carvalho, A. F., Stubbs, B., Tseng, P., Wang, L., & Lin, P. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70041
“…all inclusion criteria and were selected for data extraction (Abreu et al. 2019; Allison et al. 2023; Aroda et al. 2017, 2019; Athauda et al. 2017; Aviles‐Olmos et al. 2013; Best et al. 2011; Blackman et al. 2016; Bliddal et al. 2024; Buse et al. 2023 Rosenstock et al. 2019; Rubino et al. 2021;…”
Physiopathology and treatment of multiple system atrophy
Cuina, M. L. (2019) · theses.fr (ABES) · doi:10.70675/b2d23428z84cfz4677za1fez0837630e203b
Impacts de la modulation du cholestérol cérébral dans la maladie de Parkinson
Rousselot, L. (2023) · theses.fr (ABES) · doi:10.70675/c92a8ee9zd623z4ebbz813az17685082f328
Diabetic signature on Parkinson’s disease: Insights into pathophysiology and therapeutic repurposing
Venugopal, R., Vijayaraghavan, A., Krishnan, S., Puthenveedu, D. K., Surendran, V., & Sachithanandan, S. (2026) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_64_25
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Eijsvogel, P. P. N. M., Smits, L. M. G., Kremer, P. H. C., & Groeneveld, G. J. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70315 · Cited by 1
Arrar, A., Mallem, S. E., Ravier, M. A., & Costes, S. (2026) · médecine/sciences · doi:10.1051/medsci/2026065
Wang, Z., Zhao, W., Chen, X. M., Zhao, S. P., Li, X., Yang, Q., Zong, F., & Zhang, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1820128
Sapelli, B. L., Krause, M. V. D. B., de Sousa, I. F., & Pimentel, L. R. (2026) · Arquivos Catarinenses de Medicina · doi:10.63845/y9hpkm48
Chen, Y., Zhang, Z. K., Liu, Z., Lv, T., Ye, M., Yan, J., & Zhang, M. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1858507 · Cited by 3
Cassataro, G., Scriffignano, S., Geraci, G., Augello, G., Grasso, M. A., D’Ippolito, M. E., Puleo, M. G., Cadelo, M., Renda, M., & Tuttolomondo, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04468-x · Cited by 1
Yu, T., Mai, Q., Wang, Q., Pan, M., Xiong, Y., Kuang, L., & Liu, H. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1894856
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Hölscher, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1906426 · Cited by 1
Grasso, M., Maggio, V., Caraci, F., & Rizzo, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03760-8 · Cited by 1
Schechter, M., Sehtman-Shachar, D. R., Fishkin, A., Mosenzon, O., Cukierman‐Yaffe, T., Sharon, R., Leibowitz, G., Arkadir, D., & Aharon‐Hananel, G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70315 · Cited by 1
Devi, D., Rani, A., Singh, J., Quasmi, M. N., Jangra, A., & Kumar, D. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02731-y
Appetitzügler bei Parkinson? Zwischen Mangelernährung und GLP1-Agonisten
Ceballos-Baumann, A. (2026) · Nervenheilkunde · doi:10.1055/a-2911-3700
Future directions in Parkinson's disease pharmacotherapy
Abo‐elnour, D. E., Helal, M. M., Ahmed, B. A., Abouelmagd, M. E., Hefnawy, M. T., Alsalhi, H. K., Abdelkader, A., Al-dardery, N. M., & Alshwayyat, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27702-3.00025-x
Repurposing existing drugs for Parkinson's disease management
Abouelmagd, M. E., Messak, M., Gadelmawla, A. F., & Kundu, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-54032-5.00007-3
Gli standard di cura terzo step: incretina + metformina
Giandalia, A., Romeo, E. L., Zingale, R., Alecci, U., & Russo, G. T. (2014) · MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.